SCHADE CHRISTIAN S reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Christian S. Schade received a grant of 17,700 restricted stock units (RSUs) tied to the company’s common stock. The award was made at no cash cost under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Schade elected to defer delivery of the underlying shares until a lump-sum payment is made in the calendar year after his service on the Board ends, or a later year he elected. Following this grant, he holds 17,700 RSUs directly from this award.
Integra LifeSciences Holdings Corporation reported the results of its 2026 Annual Meeting of Stockholders held on May 7, 2026. Stockholders approved Amendment No. 3 to the Fifth Amended and Restated 2003 Equity Incentive Plan, increasing the number of common shares available for equity awards by 3,550,000 shares.
All director nominees were elected, each receiving over 62 million votes in favor, with broker non-votes of 3,918,311 for each nominee. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 fiscal year and approved, on an advisory and non-binding basis, the compensation of the named executive officers.
Integra LifeSciences delivered higher revenue but remained unprofitable for the quarter ended March 31, 2026. Total revenue rose to $391.9 million from $382.7 million a year earlier, led by Specialty Surgery at $283.1 million and Tissue Reconstruction at $108.8 million.
The company swung to operating income of $11.5 million from an operating loss of $15.5 million, helped by lower cost of goods sold and tighter operating expenses. Net loss narrowed significantly to $4.6 million, or $(0.06) per share, compared with a net loss of $25.3 million, or $(0.33) per share.
Cash generation improved, with operating cash flow of $9.8 million versus an outflow of $11.3 million in the prior-year quarter. The balance sheet showed cash and cash equivalents of $236.8 million, short‑term investments of $28.7 million, and total debt of about $1.87 billion. The company also recorded an $18.7 million IEEPA tariff refund receivable, providing a benefit to current-year costs.
Integra LifeSciences announced a major leadership transition, appointing longtime director and current chairman Stuart M. Essig as president and chief executive officer effective May 1, 2026, succeeding Mojdeh Poul, who departed as CEO and board member on April 30, 2026.
Under his new employment agreement, Mr. Essig will receive a $1,075,000 base salary, a target annual bonus equal to 125% of salary, and one-time equity awards of $4 million in restricted stock units and $4 million in stock options, each vesting over three years. The agreement also provides for severance of up to 2.99 times salary plus target bonus, continued health coverage, and accelerated equity vesting in certain terminations and change in control scenarios.
The company entered into a separation agreement with Ms. Poul that includes a cash payment of $566,526 and reimbursement of up to $25,000 in legal fees, along with previously disclosed severance benefits. Integra also created a new chief commercial officer role, appointing Michael McBreen, who will receive a $660,000 salary, a 90% target bonus, and a $1 million promotion equity award, with broader commercial responsibilities designed to sharpen customer and market focus.
Integra LifeSciences reported first quarter 2026 revenue of $391.9 million, up 2.4% year over year and 1.3% on an organic basis. GAAP results improved but remained a loss, at $(0.06) per diluted share versus $(0.33) a year earlier.
Profitability strengthened on an adjusted basis. Adjusted gross margin rose to 64.1% from 62.2%, adjusted EBITDA reached $76.2 million (19.4% of revenue), and adjusted EPS increased to $0.54 from $0.41. Tissue Reconstruction grew 6.7% reported, while Specialty Surgery was roughly flat.
The company reaffirmed 2026 revenue guidance of $1.662–$1.702 billion and raised its 2026 adjusted EPS outlook to $2.40–$2.50 from $2.30–$2.40, citing first-quarter benefits from IEEPA tariffs. Net debt was $1.60 billion with a total leverage ratio of 4.1x and total liquidity of about $488 million.
Integra LifeSciences Holdings Corporation amended its existing $150 million accounts receivable securitization facility, originally entered into in 2018, by executing amendments to its Receivables Financing Agreement and Purchase and Sale Agreement.
The amendments extend the facility’s scheduled termination date to April 10, 2029 and adjust certain customary representations, covenants and concentration limits related to the receivables backing the facility. These changes are intended to keep the funding structure in place to support ongoing liquidity and working capital needs.
Integra LifeSciences Holdings Corporation is asking stockholders to elect eight directors, ratify PricewaterhouseCoopers LLP, approve executive compensation on an advisory basis, and adopt an amendment to its 2003 Equity Incentive Plan at the 2026 annual meeting.
For 2025, Integra reported $1.64 billion in revenue, up 1.5%, driven by Codman Specialty Surgical growth, but recorded a GAAP net loss of $516.5 million as it invested heavily in quality systems, supply chain reliability and facility upgrades. Adjusted EBITDA was $317.5 million with operating cash flow of $50 million. The company highlights progress on an enterprise transformation, product relaunches such as PriMatrix and Durepair, new neurosurgical technologies, and ongoing work to resolve FDA-related quality commitments while embedding broader corporate sustainability and governance practices.
Integra LifeSciences Holdings Corp Schedule 13G/A: The Vanguard Group filed an amendment reporting 0 shares beneficially owned and 0% of the common stock as of the amendment. The filing states Vanguard implemented an internal realignment on January 12, 2026 and is reporting certain subsidiaries separately in reliance on SEC Release No. 34-39538.
The amendment is signed by a Vanguard officer and explains that subsidiaries or business divisions that formerly were reported with The Vanguard Group will now report disaggregated ownership; Vanguard states it no longer is deemed to beneficially own securities held by those subsidiaries.
INTEGRA LIFESCIENCES executive Harvinder Singh, EVP & President, International, reported compensation-related equity activity. On March 11, 2026, he received a grant of 60,865 restricted stock units, which will vest 33%, 33% and 34% on the first, second and third anniversaries of the March 11, 2026 grant date.
Several earlier restricted stock unit awards vested on their second and third anniversaries, leading to the conversion of 20,138 units into common stock over March 10–11, 2026. To cover tax obligations, a total of 6,652 common shares were withheld at prices of $9.55 and $9.61 per share.
After these transactions, Singh directly holds 35,422 shares of common stock. The filing reflects routine vesting and tax withholding rather than open-market buying or selling.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & President, CSS, received a grant of 92,108 restricted stock units that will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.
To cover tax obligations, he disposed of 2,354 and 7,247 shares of common stock at $9.55 and $9.61 per share through tax-withholding transactions, not open-market sales. Following these transactions, he directly holds 60,743 common shares and the new 92,108 RSUs.